Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders

American Journal of Surgical Pathology

Volumn 40, Issue 4, 2016, Pages 443-452

  Xu, Jie ^a   Sun, Heather H ^a   Fletcher, Christopher D M ^a   Hornick, Jason L ^a   Morgan, Elizabeth A ^a   Freeman, Gordon J ^b   Stephen Hodi, F ^b,c   Pinkus, Geraldine S ^a   Rodig, Scott J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Medical Oncology ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Histiocytes; PD L1; PD L2

Indexed keywords

BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2;

AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIKUCHI DISEASE; LANGERHANS CELL HISTIOCYTOSIS; MALE; METABOLISM; MIDDLE AGED; SARCOIDOSIS; SINUS HISTIOCYTOSIS;

AGED; ANTIGENS, CD274; BIOMARKERS; FEMALE; HISTIOCYTIC NECROTIZING LYMPHADENITIS; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, SINUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; SARCOIDOSIS;

EID: 84954466846     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000590     Document Type: Article

References (26)

1. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
2. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268.
3. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
4. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-477.
5. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
7. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
8. Taube JM, Klein AP, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenviron-ment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;1:5064-5075.
9. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-319.
10. Grogan TM, Pileri SA, Chan JKC, et al. Histiocytic sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: IARC Press; 2008:356-357.
11. Jaffe R, Weiss LM, Facchetti F. Tumours derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press; 2008:358-360.
12. Weiss LM, Grogan TM, Chan JKC. Interdigitating dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: IARC Press; 2008:361-362.
13. Chan JKC, Pileri SA, Delsol G, et al. Follicular dendritic cell sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: IARC Press; 2008:363-364.
14. Shi M, Roemer MGM, Chapuy B, et al. Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715-1723.
15. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462-3473.
16. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568-571.
17. Craft JE. Follicular helper T Cells in immunity and systemic autoimmunity. Nat Rev Rhematology. 2012;8:337-347.
18. Baughman RP, Lower EE. Treatment of sarcoidosis. Clin Rev Allerg Immunol. 2015;49:79-92.
19. Pilichowska ME, Pinkus JL, Pinkus GS. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease) lesional cells exhibit an immature dendritic cell phenotype. Hematopathology. 2009;131:174-182.
20. El Demellawy D, Young JL, de Nanassy J, et al. Langerhans cell histiocytosis: a comprehensive review. Pathology. 2015;47:294-301.
21. Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26:351-356.
22. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev. 2012;12(April):252-264.
23. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-3277.
24. Ohshima K, Haraoka S, Takahata Y, et al. Interferon-gamma, interleukin-18, monokine induced by interferon-gamma and inter-feron-gamma-inducible protein-10 in histiocytic necrotizing lymphadenitis. Leuk Lymphoma. 2002;43:1115-1120.
25. Prior C, Haslam PL. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to cortico-steroid therapy. Am Rev Respir Dis. 1991;143:53-60.
26. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. PNAS. 2003;100:5336-5534.